about 70,000 newly diagnosed breast cancer cases are registered every year (15) . In most cases, breast cancer development is due to sporadic genetic events, which lead to an activation of oncogenes and/or inactivation of tumor suppressor genes. Only in 5% of cases, can a hereditary component be detected; most of these are mutations in the BRCA genes (16) (17) (18) . Other risk factors for breast cancer development are nulliparity, early menarche, late menopause and late age at pregnancy. Thereby, the age of the first full-term pregnancy seems to play a role as a risk factor, by increasing levels of hCG, which is thought to have a protective effect on breast cells by increasing differentiation (19) . Early age of full-term pregnancy has a protective effect against breast cancer (20) . Nowadays, diagnosis and screening techniques are rather sophisticated (21) , so that most breast cancer cases can be detected in an early stage, when therapy is still effective, thereby increasing disease-free and overall survival (22) (23) (24) (25) . Treatment is mostly done by surgery, radiotherapy and chemotherapy, depending on tumor stage and differentiation. Thus 5-year survival rates of 80% are achieved (15) .
Role of hCG in endometrial adenocarcinoma
HCG as a tumor marker HCG was described as a tumor marker as early as 1982, when a collective of 456 different cancers was analyzed using the immunoperoxidase technique. Among these cases, 18 .9% of endometrial adenocarcinomas were positive for hCG, and it was found that poorly differentiated and/or invasive tumors had the highest expression levels of hCG (26, 27) . Shortly after these studies, the occurrence of hCG and carcinoembryonic antigen (CEA) were immunohistologically studied in cervical and endometrial adenocarcinomas and were regarded as useful markers in the characterization of adenocarcinomas of the uterus (28) . The appearance of this marker in the blood of patients with gynecological tumors could also be helpful in evaluating the therapy response or might indicate the development of recurrence or remote metastasis (29) . At the same time, it was found that the free β-subunit of hCG, asialo-free β-subunit and its core glycopeptide, referred to as urinary gonadotropin fragments (UGFs), could be detected in the urine of cancer patients, especially of endometrial adenocarcinoma patients, and that the detection of UGFs also gives some hints regarding the stage of disease (1) .
A case report from 1991 confirmed these data, reporting some poorly differentiated endometrial adenocarcinomas with high hCG β-subunit levels in blood, which in fact dropped after treatment, but nevertheless the patients suffered a rapid progression and recurrence and died soon afterwards (30) . Similar data were reported in 1993, where hCG levels of 2 placental tumors were compared, and the patient with the lower levels died earlier than the patient with the high levels, so it was suggested that hCG could not be regarded as a general and unique tumor marker (31, 32) .
HCG is known to bind the LH receptor, so an analysis of LH receptor expression was an obvious approach. Northern and Western blotting demonstrated that the level of LH receptor proteins in patients with endometrial adenocarcinomas is much higher than in those with normal endometrium, and the level even increases with increasing tumor grade, highlighting the importance of this receptor in endometrial tumorigenesis (33) (34) (35) . In 1995, it was shown that the free β-subunit of hCG especially can be used as a tumor marker, while the significance of the α-subunit is of minor importance (36) . Two further case reports from 1998 again demonstrated the importance of β-hCG as a tumor marker, connected with aggressive disease, metastasis formation and poor patient survival (37) (38) (39) . In 2004 another case of endometrial adenocarcinoma was reported, which even only produced free β-subunit of hCG, thereby producing contradictory results between serum and urine analyses (6, 40) . Endometrial adenocarcinomas with low serum hCG levels, in contrast, were shown to have a better prognosis (41) (42) (43) . The finding that LH/hCG are expressed in primary endometrial adenocarcinomas and that this expression correlates with cell invasiveness led to the conclusion that recurrent and metastatic endometrial adenocarcinomas expressing these molecules could benefit from therapies lowering the LH/hCG levels with gonadotropin-releasing hormone (GnRH) analogues. Thus LH/hCG can be regarded as a prognostic factor and also a therapeutic target (44) . Furthermore, also in patients with low risk of endometrial adenocarcinoma, the expression levels of LH/hCG, analyzed together with other clinicopathological factors, can help to predict recurrence risk in low-risk endometrial adenocarcinoma patients (45) .
Tumorigenesis mechanism of tumorigenesis involving hCG
The mechanisms by which hCG influences cellular reactions are difficult to understand. In 1999 it was found that the mitogen-activates protein kinase (MAPK) pathway could be regulated by platelet-activating factor (PAF) and hCG in the endometrial adenocarcinoma cell line Hec-1B. The cells were therefore pretreated with medroxyprogesterone acetate and estradiol. PAF and hCG then activates the MAPK pathway, which in turn activates the cyclooxygenase 2 (COX-2) expression, but protein kinase A is still upstream of this signaling pathway (46) . It was confirmed that the expression of the LH-/hCG receptor correlated with cell invasiveness (47) and was a mediator of hCG action (48) .
The high expression levels of LH receptor and their obvious correlation with tumor grading led to an analysis in the endometrial adenocarcinoma cell line Hec-1A. Scientists recognized that the binding of LH/hCG to the respective receptor leads to an activation of cAMP kinase (PKA) and further downstream activations of β-1-integrin receptors and matrix metalloproteinase-2 (MMP2) secretion. These mechanisms could also be shown in primary endometrial carcinomas where they produced an increase in cell invasiveness, as demonstrated in Matrigel assays. The conclusion of this analysis was that an inhibition of LH secretion by GnRH analogues could be a new treatment option for endometrial adenocarcinomas (49, 50) . Furthermore, it does not seem to make a difference for LH receptor activation if hCG, hCG β-subunit or the hyperglycosylated form of hCG β-subunit bind to this receptor (51) .
In contrast to these results were those of a study from 2007, in which the LH receptor and its response to hCG was analyzed in the Ishikawa cell line. Although the LH receptor was confirmed to be present as a full-length molecule, it could not be activated by hCG for downstream signaling. It was thus presumed that the Ishikawa cells used a pathway different from the conventional LH/hCG receptor signaling pathway (52) .
A recent study by the group of Chen et al demonstrated that hCG induced the overexpression of β1,4galactosyltransferase I (β1,4GalT I) in RL95 cells. β1,4GalT I in turn regulates the expression of molecules such as TIMP-1, LN and MMPs, which alter cell adhesive properties. It was furthermore demonstrated that hCG also increased epidermal growth factor receptor (EGFR) signaling, a process which normally plays a role in embryo implantation, a process which, further, is rather similar to tumor invasion (53) . From these results it could be concluded that hCG has different tasks within the female body, which have not yet been fully clarified.
Role of hCG in breast cancer

HCG as a tumor marker
The fact that hCG might serve as a tumor marker in breast cancer was already recognized at the beginning of the 1970s (54, 55) . Also the prognostic relevance of hCG (in particular, that of the α-subunit of hCG was shown early) in the correlation of the occurrence of this subunit with lymph node metastases and a poorer prognosis for patient survival was depicted (56) . In the following years, the importance given to hCG as a breast cancer marker decreased a lot (57, 58) , although it could be demonstrated that malignant breast cancer cells produce hCG, as confirmed by the intracellular location of the molecule (59) . In the beginning of the 1980s, there was doubt regarding the usefulness of hCG as a serum marker in metastatic breast cancer and its significance in monitoring palliative treatment, as other markers such as alkaline phosphatase (AP), CEA and tissue polypeptide antigen (TPA) had higher rates of occurrence and could be related to other tumor characteristics (60) . For hCG, no clinical relevance could be seen (61) (62) (63) (64) , especially as it was found to also be expressed in healthy breast tissue (65) . But scientists in this period agreed that hCG was expressed to a higher degree in postmenopausal women (63, 66) .
A study from 1988 finally recognized hCG as a tumor marker for breast cancer again (67) . Almost 10 years later, the role of hCG in breast cell differentiation was clarified, and its inhibitory role in mammary carcinogenesis was presumed (68) . A few years later, a correlation between hCG and progesterone receptor was found, suggesting a regulation of hCG expression by progestins, but no correlation between hCG expression and disease-free and overall survival was seen (69) . A multimarker reverse transcriptase polymerase chain reaction (RT-PCR) assay could then demonstrate a correlation of hCG and a tumor-associated antigen (MAGE-A3) with tumor size (70) .
In general, hCG was described as a useful real-time PCR marker (71) for the detection of circulating tumor cells -for example, in combination with mammaglobin (hMAM) (72) or cytokeratin 19 (73) . The RT-PCR technique with CK19, CK20 and hCG as marker genes was also used to demonstrate that fine-needle aspiration of breast tissue might introduce cancer cells in the blood stream (74) . Again a few years later a coherence between the messenger RNA (mRNA) presence of hCG β-subunit genes 3, 5 and 8 and relapse-free survival could be shown by molecular beacon reverse transcriptase PCR (75) . HCG could furthermore be correlated to inhibin expression, and a high expression of hCG was measured in apocrine tumor types, so that it could help to characterize tumors (76) .
A prediction of metastatic outgrowth and therapy response and monitoring was promoted by the group of Francia et al in 2008 (77) . Furthermore, it was shown that there was no difference in the significance of total hCG and free β-subunit of hCG, as both could be related to maternal breast cancer risk (78) . Recently it could even be demonstrated that hCG promotes normal breast cell differentiation in animal models, and administration of hCG or generally higher hCG levels prevent occurrence of breast cancer development in mice, but no inverse correlation between pregnancy and reduced breast cancer risk was shown (79) .
Tumorigenesis mechanism of tumorigenesis involving hCG
In 1994, scientists began to clarify the mechanisms of the functioning of hCG. In hCG-treated human breast cancer cell lines, some mRNAs and proteins were produced to a higher extent, while others were down-regulated in comparison with untreated control cells, but the assignment of these mRNAs and proteins respectively could not be clarified yet (80) . In the experiments that followed, a higher expression of p53, c-myc and ICE could be described in hCG-treated cells, so that hCG seemed to exert an apoptotic influence on breast cancer cells (81) (82) (83) (84) . It could again be shown, that the growth inhibitory effect of hCG on breast cancer cells was dependent on the presence of the LH/hCG receptor (85) . Also the expression of inhibin was found to be elevated after hCG treatment, leading to mammary gland differentiation and tumor regression (86) . Thus inhibin and hCG effectuates an increase in histone acetylation (87) . In contrast to that, hCG was found to stimulate the growth of tumor cells in the presence of estrogen and estrogen response elements (ERE) by increasing ERE-mediated transcription. Therefore GnRH analogues could be effective therapeutic agents in women suffering from postmenopausal breast cancer (88, 89) .
Furthermore, hCG seems to influence the expression of Hox genes, depending on the splice variant of the LH receptor that is present in the respective cell type (87) . Not only genes for apoptosis and inhibition of cell proliferation but also genes regulating DNA repair and the impaired binding of carcinogens to the DNA are highly expressed due to the action of hCG (90) . Furthermore, hCG not only leads to a reduction of cell proliferation but obviously also to a decrease in cell invasion. These 2 effects are provoked by a down-regulation of NF-kB and AP-1 via a cAMP-dependent protein kinase signaling pathway driven by hCG (91) .
In contrast to the protective effects that hCG has in most breast cancer cases, in pregnancy-associated breast cancer, hCG seems to play a different role: in this special type of breast cancer, which occurs during pregnancy or within 1 year after delivery, it seems to increase neovascularization via vascular endothelial growth factor (VEGF), a process which is crucial to metastatic outgrowth (92) . Another reason for these pregnancy-induced tumors could be an up-regulation of certain molecules from the Wnt-signaling pathwayfor example, Wnt 5b and 7b (93) .
Returning to the subject of the cancer-protective effects, which are the major modes of action of hCG, it was recognized that cancer protection is mediated by α-fetoprotein (AFP), in the process through which hCG elicits AFP from the nonpregnant liver (94) . The high levels of hCG found in patients suffering from choriocarcinoma were also reported to be protective against breast cancer (95) . The ambivalent function of hCG as a breast cancer promoting or protecting agent is also seen in invasive vs. noninvasive breast cancer: In invasive tumors of the breast, an up-regulation of the LH/hCG receptor was found, indicating that hormones which target these receptors could favor the generation of mammary tumors (96) . There is evidence, for example, that there are a low number of LH/ hCG receptors on breast cancer cells, which suggest a more indirect way of signaling effects, and that these signaling effects may occur through the ovaries (20) .
Whether hCG favors or impairs tumor formation is obviously dependent on the receptors, which are found at the surface of breast epithelial cells. This was demonstrated by Iezzi et al, who used a mouse model for their analyses and found that tumor progression via hCG occurs, if mammary cells are positive for the expression of LH/hCG or ERBB-2 receptor (97). Additionally, there are indirect endocrine effects of the cells, which influence cancer outgrowth (98) . As already presumed in 2002, hCG influences histone modification, in turn affecting chromatin condensation levels and thereby regulating gene expression. The occurrence of hCG was correlated to the presence of me2H3K9 and me3H3K27, which are known markers for heterochromatin or facultative heterochromatin, respectively. Thus the genomic structure of breast cell differentiation is kept up, and carcinogenesis is prevented (99) . In conclusion it can be said that in most cases hCG has a protective effect on breast cancer formation by reducing cell proliferation and increasing differentiation (100, 101) .
HCG in breast cancer therapy
It was recognized early that a large number of patients with metastatic breast cancer had high hCG levels in their serum, and that levels corresponded to responses to combination chemotherapy, so hCG could be considered as a therapeutic marker (102) . But hCG administration also seemed to reduce breast cancer risk, especially in women with nonobese BMI (103) . Additionally, hCG also contributes to a higher radiosensitivity of breast cancer cells, at least in a cell culture model using MCF7 cells (in concentration of 2 IU/mL hCG at 24 hours before irradiation with 4 Gy for MCF7 cells) (7) .
Another interesting approach was to use hCG as a DNA vaccine for active-specific immunotherapy in controlling mammary tumor progression. Thus BALB/c mice were vaccinated with a plasmid carrying 6 copies of a part of the hCG DNA sequence. Vaccinated animals had higher antibody avidity and improved immunogenicity, thus this would seem to be another promising approach for combating breast cancer via hCG (104) .
As hCG also might increase rates of apoptotic cell death, it could be used preceding local or systemic therapy to improve therapy response. This presumption was confirmed by xenograft analysis and seems to be a promising approach (105) .
In 2007, another interesting study with respect to hCG in cancer therapy was performed. Women with newly diagnosed breast cancer received recombinant hCG (rhCG) 2 weeks before surgery. After surgery, tumor tissue was analyzed, and a reduction of the proliferative index and expression of estrogen and progesterone receptors were found in comparison with the control group who only received placebo. Also in metastatic breast cancer, rhCG had beneficial effects, so that further studies on this topic would be worthwhile (106) .
Also, a long-term protective effect of pregnancy hCG of breast cancer has been described in the literature, depending on age at pregnancy and breast cancer diagnosis (107, 108) . A study from 2011 even postulated that hCG prevents the formation of cancer stem cells via down-regulation of CXCR-1 expression, thereby preventing further cancer outgrowth and metastasis formation (109) . An infertility treatment with hCG was also presumed to have breast cancer-protective effects (110) .
Further interesting facts regarding hCG and its correlation with breast cancer
LH/hCG seems to play a role not only in female but also in male breast cancer, as shown in the fact that LH/hCG receptors were found during an autopsy of male breast cancer patients. But the function of these receptors in the male form of breast cancer still has to be clarified (111) .
Pregnancies from which children with Down syndrome are born are characterized by high hCG levels in the first and up to the middle of the second trimester. A large study from Norway and Sweden analyzed the effects of these high hCG levels on breast cancer risk for mothers who gave birth to Down syndrome children, and found that risk for breast cancer development increased by 23%, especially if mothers were delivering at age >30 years (112) .
Although the expression of hCGβ has been described already in many nontrophoblastic tumors, up to now there is only 1 case reported in the literature in which hCG was also found to be expressed in a phyllodes tumor, especially in the epithelioid stroma of the tumor (113) .
Conclusions
HCG is a glycoprotein, which occurs physiologically in women and even in men, but it is up-regulated during pregnancy, playing a role in nidation and nutrition of the early embryo. If the occurrence of this molecule within the body is increased without pregnancy it can stimulate tumor outgrowth. Both in endometrial adenocarcinoma and in breast cancer, hCG seems to be an important tumor marker, not only for tumor cell detection, but also for characterization. The signal transduction pathways by which hCG acts in these 2 gynecological malignancies are not yet clarified completely, but further research would be worthwhile, as hCG seems to offer possibilities for tumor treatment.
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